- Select a blog category
By Karen Taylor, Director, Centre for Health Solutions
Last month Deloitte was one of the main sponsors of the 2019 FT Global Pharmaceutical and Biotechnology Conference. This is a key event for the industry, attended by senior industry executives and financial professionals from around the world. The aim of this year’s conference was to focus a critical eye on the forces set to transform the industry in the years ahead. I was privileged to attend the conference and help man our stall where we displayed our research reports, including our report Intelligent biopharma: Powered by AI, which we launched on the first day. We also introduced our new Converge Health platform and the connected patient experience. This week’s blog shares some of the highlights that I took away from the presentations and panel debates that took place on the first day. I will return to day two in a later blog.
By Karen Taylor and Krissie Ferris, Centre for Health Solutions
Since 2008, the Deloitte US Center for Health Solutions has polled a nationally representative sample of US adults (18 and older) about their experiences and attitudes related to their health, health insurance, and health care.1 Earlier this year we helped the US Center design a global survey to help understand what consumers value most about healthcare, and their appetite for digital innovations, including their willingness to share their personal health data. The US Center collected primary data through an online survey, fielded between May and June 2019, in seven countries (Australia, Canada, Denmark, Germany, Netherlands Singapore and the UK). It then compared their responses to responses from the US consumer survey conducted in 2018. The US Centre launched their report on the survey last week.2 This week’s blog is our take on the key findings for the UK.
By Andrew Bryan, Deloitte Financial Advisory
This summer’s high profile coverage of the ‘Aussie flu’ outbreak Down Under, got me thinking about how much of the coverage is media hype, and whether there is any available data to support the fears about flu outbreaks in the Northern hemisphere. With the UK now entering the flu season, this week’s blog explores my analysis and key findings.
By Dr Mark Steedman, PhD, Manager, Centre for Health Solutions
The moustache has a fascinating history – popular at times, eschewed at others, but always competing in the popularity stakes against the beard. From a fashion symbol popularised by monarchs of the past, to practical restrictions on beards but not moustaches because of press articles linking germs with beards and rules preventing bearded men from handling food. As a result, the popularity of the beard versus the moustache has ebbed and flowed.1 I’ve seen this even in my own lifetime. While there were a few famous moustaches that adorned the faces of Hollywood stars and musicians, for the most part, the 1990s saw the moustache fall seriously out of fashion.
By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions
Next week at the 2019 Global Financial Times Pharmaceutical and Biotechnology conference in London, we will formally launch the second in our series of reports on how artificial intelligence (AI) is driving the digital transformation of biopharma. This second report, Intelligent drug discovery: Powered by AI, explores the rise of ‘disruptive AI for drug discovery’ companies and the challenges and opportunities for biopharma in using AI technologies to help find new, more precise, targeted treatments.1 This blog highlights the key takeaways from our report.
By Karen Taylor, Director, Centre for Health Solutions
Last month I participated in a panel discussion at the Technology Services Association International Technology-Enabled Care Conference on the subject of Citizen Powered Technological Enablement.1 In anticipation of the panel discussion, I agreed to write a blog on our July 2019 research report Closing the digital gap: Shaping the future of UK healthcare.2 This week, I thought I’d repurpose this blog as a Centre blog, to highlight some the challenges currently being faced in delivering a digital first NHS. Next month we will return to this issue with a focus on primary care.
By Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP
This week’s blog, by Glenn Snyder from the US firm, first appeared on the US Center for Health Solutions blog site. It was published in advance of the AdvaMed annual conference in Boston, where he led a session on transformational innovation with a panel of CEOs from three medical technology companies. During the session, they examined how innovation is changing thanks to the value-based marketplace and the evolution of digitally-enabled devices. They also discussed how start-ups and companies from outside of the medtech space are driving rapid changes in the market in ways that leverage their strength rather than traditional medtech strengths.
By Krissie Ferris, Research Analyst, Centre for Health Solutions
Cancer Research UK (CRUK) is encouraging the nation to take the ‘Veg Pledge’ this November and go vegetarian or vegan for one month.1 Those taking part can obtain plenty of tips, recipes and fundraising ideas from CRUK to help them through their challenge. Being vegan myself, and having just completed my first week at Deloitte, it was great to see so many plant-based offerings on the menu at our snazzy 1 New Street Square canteen. Providing more plant-based options is the main way employers are responding to the cultural shift that is turning more and more people towards plant-based diets (see Deloitte’s 2019 article ‘Plant-based alternatives, Driving industry M&A’).2 However, there are many other approaches that leading companies like Deloitte can take to encourage and inspire plant-based eating in the workplace. This blog explores those opportunities and the benefits of plant-based eating.
By Mark Green, Director Board Advisory
The NHS Long Term Plan (LTP) and the development of STPs, ICSs, ICPs and now PCNs (see Figure 1), not only makes for a mouthful of acronyms, but also raises the prospect of a governance headache. While the LTP requires every NHS organisation and their local partners to become part of a geographically-based ICS by April 2021, and recognises that it’s possible to implement the necessary changes without primary legislation, it also acknowledges that legislative change could make implementation easier and faster.1 However, there are currently limited signs of any primary legislation being introduced in the short to medium term to support and guide the shift in health and care policy.
By Mark Steedman, PhD, Manager, Centre for Health Solutions
This week, we have launched the first in a series of reports on artificial intelligence (AI) and its potential impact in driving the digital transformation of biopharma. This overview report, Intelligent biopharma: Forging the links across the value chain, explores the challenges and opportunities in AI adoption and the potential ways that AI might impact the different segments of the biopharma value chain (see Figure 1).1
By Elliot Birtwhistle, Deloitte Consulting
Genetic modification (GM) is the process of altering the genes of a living organism. The words invoke images of secret government labs and scientists in white hazmat suits that inject rodents with glowing liquid. The reality is somewhat more nuanced. Genetic modification either inserts a gene, or a small number of genes into a plant or animal – or ‘silences’ an existing gene(s) to produce a genetically modified organism. The applications are widespread and include medicines, consumer products and commercial agriculture. This week’s blog explores some of the issues surrounding GM foods.